NCIA’s #IndustryEssentials webinar series is our premier digital educational series featuring a variety of interactive programs allowing us to provide you timely, engaging and essential education when you need it most.

Join us for the second episode of NCIA’s #IndustryEssentials webinar series, “Advancing Cannabis Science: Research Opportunities and Safety Post-Rescheduling,” led by the Scientific Advisory Committee. This session will focus on the significant changes and opportunities for scientific research and consumer safety following the rescheduling of cannabis to a Schedule III drug.

Key learning objectives include:

• Consumer Safety Education: Learn how to ensure the safety of your customers in a landscape where cannabis is still not fully legal, addressing issues such as polypharmacy, drug testing, and managing adverse events.

• R&D Implications: Understand how rescheduling impacts research and development activities, particularly in the absence of NIDA (National Institute on Drug Abuse) constraints, and explore new opportunities for scientific innovation.

• Standardized Testing: Prepare for the demands of interstate commerce by implementing standardized testing protocols to ensure consistency and compliance across state lines.

This episode will provide vital insights for researchers, product developers, and industry stakeholders aiming to advance their scientific efforts and maintain high standards of consumer safety in a newly regulated environment. Engage with experts through a detailed Q&A session to discuss your specific concerns and opportunities.

Equip yourself with the knowledge and strategies essential for advancing cannabis science and ensuring consumer safety. Register now to join this crucial discussion!

Panelists:

Cassin Coleman
Cassin Consulting

Dr. Cynthia Shelby-Lane
ShelbyLane MD PC

Carly Bader
Willow Industries